2023-04-11 09:02:57 ET
- Nano-cap biotech IN8bio ( NASDAQ: INAB ) added ~7% pre-market Tuesday after announcing that new data from its Phase 1 trial for allogeneic cell therapy candidate INB-100 will be presented at a medical event in Europe later this month.
- An allogeneic, gamma-delta T cell therapy, INB-100, is currently undergoing the early-stage trial in patients with hematologic malignancies undergoing haploidentical stem cell transplantation (HSCT).
- Updated data from the study will be part of a presentation at the 49th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), scheduled in Paris from April 23 to 26.
- Concurrently, IN8bio ( INAB ) said that as of December 18, 2022, the data cutoff of the abstract, all four patients who received INB-100 remained in the study in complete remission (CR) with one patient reporting 32.2 months of progression-free survival.
- Read: H.C. Wainwright started its coverage on INAB with a Buy rating in August, expecting its cell therapy candidates to reach the market as early as 2025.
For further details see:
IN8bio gains on upcoming data readout for cell therapy